Rein Therapeutics Inc. (NASDAQ:RNTX) Stock Rated “Hold” by Sell-Side Analysts

Shares of Rein Therapeutics Inc. (NASDAQ:RNTX) have been given an average recommendation of “Hold” by the four analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $6.00.

A number of brokerages have commented on RNTX. Weiss Ratings downgraded shares of Rein Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 21st. HC Wainwright reiterated a “buy” rating on shares of Rein Therapeutics in a research note on Tuesday, August 18th. Finally, Maxim Group started coverage on Rein Therapeutics in a report on Monday, July 20th. They issued a “buy” rating and a $4.00 target price on the stock.

Rein Therapeutics Stock Performance

Shares of Rein Therapeutics stock opened at $0.79 on Friday. The business has a 50-day simple moving average of $0.79 and a 200-day simple moving average of $1.01. Rein Therapeutics has a one year low of $0.69 and a one year high of $2.18. The company has a market cap of $68.50 million, a PE ratio of -0.46 and a beta of 1.35.

Rein Therapeutics (NASDAQ:RNTX) last issued its earnings results on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.17. On average, sell-side analysts predict that Rein Therapeutics will post -0.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Chicago Partners Investment Group LLC increased its holdings in shares of Rein Therapeutics by 32.2% in the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock valued at $53,000 after acquiring an additional 10,000 shares during the last quarter. Sequoia Financial Advisors LLC acquired a new position in Rein Therapeutics in the second quarter valued at approximately $260,000. Gagnon Securities LLC boosted its holdings in Rein Therapeutics by 5.0% in the fourth quarter. Gagnon Securities LLC now owns 240,220 shares of the company’s stock valued at $279,000 after purchasing an additional 11,528 shares in the last quarter. Sigma Planning Corp increased its stake in Rein Therapeutics by 41.0% in the first quarter. Sigma Planning Corp now owns 348,677 shares of the company’s stock valued at $453,000 after purchasing an additional 101,400 shares during the last quarter. Finally, Velan Capital Investment Management LP acquired a new stake in Rein Therapeutics during the second quarter worth approximately $1,768,000. 90.89% of the stock is owned by institutional investors and hedge funds.

About Rein Therapeutics

Rein Therapeutics, Inc (NASDAQ:RNTX) is a clinical-stage biotechnology company focused on developing therapies for fibrotic diseases, including conditions affecting the lungs and other organs. The company’s research is aimed at addressing diseases in which abnormal tissue scarring can impair organ function and lead to serious, progressive health problems.

Rein Therapeutics’ lead development program is deupirfenidone, an investigational therapy being studied for idiopathic pulmonary fibrosis, a chronic lung disease characterized by progressive scarring of lung tissue.